As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

In June 2022, the highest level of support for the use of COVID vaccine mandates for international travel was reported among people surveyed in India at **** percent. On the other hand, the lowest level of support for the use of such a mandate was reported in South Africa at **** percent. This statistic illustrates the level of support for using COVID vaccine mandate for international travel in 2022, by country.

As of March 15, 2023, Seychelles was the African country with the highest coronavirus (COVID-19) vaccination rate, with around 205 doses administered per 100 individuals. Mauritius and Rwanda followed with 201 and 190 doses per 100 people, respectively. Ranking fourth, Morocco had a vaccination rate of approximately 148 doses per 100 people, registering the third-highest number of inoculations after Egypt and Nigeria. In South Africa, the most affected country on the continent, the vaccination rate instead reached around 64 per 100 population.

How did Africa obtain the vaccines?

Vaccines in Africa were obtained in different ways. African nations both purchased new doses and received them from other countries. At the beginning of the vaccination campaigns, donations came from all over the world, such as China, the United Arab Emirates, India, and Russia. The United Nations-led COVAX initiative provided Oxford/AstraZeneca and Pfizer/BioNTech doses to several African countries. Within this program, the continent received nearly 270 million doses as of January 2022. Moreover, the vaccination campaign has also been an occasion for intra-African solidarity. Senegal has, for instance, donated vaccines to the Gambia, while in January 2021, Algeria announced that it would have shared its supply with Tunisia.

COVID-19 impact on the African economy

The spread of COVID-19 negatively affected socio-economic growth in Africa, with the continent’s Gross Domestic Product (GDP) contracting significantly in 2020. Specifically, Southern Africa experienced the sharpest decline, at minus six percent, followed by North Africa at minus 1.7 percent. Most of Africa’s key economic sectors were hit by the pandemic. The drop in global oil prices led to a crisis in the oil and gas sector. Nigeria, the continent’s leading oil-exporting country, witnessed a considerable decrease in crude oil trade in 2020. Moreover, the shrinking number of international tourist arrivals determined a loss of over 12 million jobs in Africa’s travel and tourism sector. Society has also been substantially affected by COVID-19 on the poorest continent in the world, and the number of people living in extreme poverty was estimated to increase by around 30 million in 2020.

Global Covid-19 Data

Global Covid-19 data on cases, deaths, vaccinations, and more

By Valtteri Kurkela [source]

About this dataset

The dataset is constantly updated and synced hourly to ensure up-to-date information. With over several columns available for analysis and exploration purposes, users can extract valuable insights from this extensive dataset.

Some of the key metrics covered in the dataset include:

1. Vaccinations: The dataset covers total vaccinations administered worldwide as well as breakdowns of people vaccinated per hundred people and fully vaccinated individuals per hundred people.

2. Testing & Positivity: Information on total tests conducted along with new tests conducted per thousand people is provided. Additionally, details on positive rate (percentage of positive Covid-19 tests out of all conducted) are included.

3. Hospital & ICU: Data on ICU patients and hospital patients are available along with corresponding figures normalized per million people. Weekly admissions to intensive care units and hospitals are also provided.

4. Confirmed Cases: The number of confirmed Covid-19 cases globally is captured in both absolute numbers as well as normalized values representing cases per million people.

5.Confirmed Deaths: Total confirmed deaths due to Covid-19 worldwide are provided with figures adjusted for population size (total deaths per million).

6.Reproduction Rate: The estimated reproduction rate (R) indicates the contagiousness of the virus within a particular country or region.

7.Policy Responses: Besides healthcare-related metrics, this comprehensive dataset includes policy responses implemented by countries or regions such as lockdown measures or travel restrictions.

8.Other Variables of InterestThe data encompasses various socioeconomic factors that may influence Covid-19 outcomes including population density,membership in a continent,gross domestic product(GDP)per capita;

For demographic factors: -Age Structure : percentage populations aged 65 and older,aged (70)older,median age -Gender-specific factors: Percentage of female smokers -Lifestyle-related factors: Diabetes prevalence rate and extreme poverty rate

1. Excess Mortality: The dataset further provides insights into excess mortality rates, indicating the percentage increase in deaths above the expected number based on historical data.

The dataset consists of numerous columns providing specific information for analysis, such as ISO code for countries/regions, location names,and units of measurement for different parameters.

Overall,this dataset serves as a valuable resource for researchers, analysts, and policymakers seeking to explore various aspects related to Covid-19

How to use the dataset

Introduction:

• Understanding the Basic Structure:

  • The dataset consists of various columns containing different data related to vaccinations, testing, hospitalization, cases, deaths, policy responses, and other key variables.
  • Each row represents data for a specific country or region at a certain point in time.

• Selecting Desired Columns:

  • Identify the specific columns that are relevant to your analysis or research needs.
  • Some important columns include population, total cases, total deaths, new cases per million people, and vaccination-related metrics.

• Filtering Data:

  • Use filters based on specific conditions such as date ranges or continents to focus on relevant subsets of data.
  • This can help you analyze trends over time or compare data between different regions.

• Analyzing Vaccination Metrics:

  • Explore variables like total_vaccinations, people_vaccinated, and people_fully_vaccinated to assess vaccination coverage in different countries.
  • Calculate metrics such as people_vaccinated_per_hundred or total_boosters_per_hundred for standardized comparisons across populations.

• Investigating Testing Information:

  • Examine columns such as total_tests, new_tests, and tests_per_case to understand testing efforts in various countries.
  • Calculate rates like tests_per_case to assess testing efficiency or identify changes in testing strategies over time.

• Exploring Hospitalization and ICU Data:

  • Analyze variables like hosp_patients, icu_patients, and hospital_beds_per_thousand to understand healthcare systems' strain.
  • Calculate rates like icu_patients_per_million or hosp_patients_per_million for cross-country comparisons.

• Assessing Covid-19 Cases and Deaths:

  • Analyze variables like total_cases, new_ca...

Context

The data is collected from OWID (Our World in Data) GitHub repository, which is updated on daily bases.

Content

This dataset contains only one file vaccinations.csv, which contains the records of vaccination doses received by people from all the countries. * location: name of the country (or region within a country). * iso_code: ISO 3166-1 alpha-3 – three-letter country codes. * date: date of the observation. * total_vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again. * total_vaccinations_per_hundred: total_vaccinations per 100 people in the total population of the country. * daily_vaccinations_raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily_vaccinations instead. * daily_vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here. * daily_vaccinations_per_million: daily_vaccinations per 1,000,000 people in the total population of the country. * people_vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same. * people_vaccinated_per_hundred: people_vaccinated per 100 people in the total population of the country. * people_fully_vaccinated: total number of people who received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1. * people_fully_vaccinated_per_hundred: people_fully_vaccinated per 100 people in the total population of the country.

Note: for people_vaccinated and people_fully_vaccinated we are dependent on the necessary data being made available, so we may not be able to make these metrics available for some countries.

Acknowledgements

This data collected by Our World in Data which gets updated daily on their Github.

Inspiration

Possible uses for this dataset could include: - Sentiment analysis in a variety of forms - Statistical analysis over time.

As of the end of 2020, the State of Israel, with a population of 9.3 million, had administered more COVID-19 vaccine doses than all countries aside from China, the US, and the UK. Moreover, Israel had administered almost 11.0 doses per 100 population, while the next highest rates were 3.5 (in Bahrain) and 1.4 (in the United Kingdom). All other countries had administered less than 1 dose per 100 population. While Israel’s rollout of COVID-19 vaccinations was not problem-free, its initial phase had clearly been rapid and effective. A large number of factors contributed to this early success, and they can be divided into three major groups. The first group of factors consists of long-standing characteristics of Israel which are extrinsic to health care. They include: Israel’s small size (in terms of both area and population), a relatively young population, relatively warm weather in December 2020, a centralized national system of government, and well-developed infrastructure for implementing prompt responses to large-scale national emergencies. The second group of factors are also long-standing, but they are health-system specific. They include: the organizational, IT and logistical capacities of Israel’s community-based health care providers, the availability of a cadre of well-trained, salaried, community-based nurses who are directly employed by those providers, a tradition of effective cooperation between government, health plans, hospitals, and emergency care providers – particularly during national emergencies; and support tools and decisionmaking frameworks to support vaccination campaigns. The third group consists of factors that are more recent and are specific to the COVID-19 vaccination effort. They include: the mobilization of special government funding for vaccine purchase and distribution, timely contracting for a large amount of vaccines relative to Israel’s population, the use of simple, clear and easily implementable criteria for determining who had priority for receiving vaccines in the early phases of the distribution process, a creative technical response that addressed the demanding cold storage requirements of the Pfizer-BioNTech COVID-19 vaccine, and well-tailored outreach efforts to encourage Israelis to sign up for vaccinations and then show up to get vaccinated. While many of these facilitating factors are not unique to Israel, part of what made the Israeli rollout successful was its combination of facilitating factors (as opposed to each factor being unique separately) and the synergies it created among them. Moreover, some high-income countries (including the US, the UK, and Canada) are lacking several of these facilitating factors, apparently contributing to the slower pace of the rollout in those countries.

IntroductionIn relatively wealthy countries, substantial between-country variability in COVID-19 vaccination coverage occurred. We aimed to identify influential national-level determinants of COVID-19 vaccine uptake at different COVID-19 pandemic stages in such countries.MethodsWe considered over 50 macro-level demographic, healthcare resource, disease burden, political, socio-economic, labor, cultural, life-style indicators as explanatory factors and coverage with at least one dose by June 2021, completed initial vaccination protocols by December 2021, and booster doses by June 2022 as outcomes. Overall, we included 61 European or Organisation for Economic Co-operation and Development (OECD) countries. We performed 100 multiple imputations correcting for missing data and partial least squares regression for each imputed dataset. Regression estimates for the original covariates were pooled over the 100 results obtained for each outcome. Specific analyses focusing only on European Union (EU) or OECD countries were also conducted.ResultsHigher stringency of countermeasures, and proportionately more older adults, female and urban area residents, were each strongly and consistently associated with higher vaccination rates. Surprisingly, socio-economic indicators such as gross domestic product (GDP), democracy, and education had limited explanatory power. Overall and in the OECD, greater perceived corruption related strongly to lower vaccine uptake. In the OECD, social media played a noticeable positive role. In the EU, right-wing government ideology exhibited a consistently negative association, while cultural differences had strong overall influence.ConclusionRelationships between country-level factors and COVID-19 vaccination uptake depended on immunization stage and country reference group. Important determinants include stringency, population age, gender and urbanization, corruption, government ideology and cultural context.

In the first half of 2021, Israel had been ahead of other countries concerning the speed of its rollout and coverage of COVID-19 vaccinations. During that time, Israel had implemented a vaccine certificate policy, the “Green Pass Policy” (GPP), to reduce virus spread and to allow the safe relaxation of COVID-19 restrictions in a time of great uncertainty. Based on an analysis of GPP regulations and public statements compiled from the Israeli Ministry of Health website, we describe the design and implementation of the GPP. We also look back and discuss lessons learned for countries that are considering a GPP policy, given the current upsurge of the Delta variant as of summer 2021. To reduce equity concerns when introducing a GPP, all population groups should be eligible for the vaccine (contingent on approval from the manufacturer) and have access to it. Alternatively, health authorities can grant temporary certificates based on a negative test. We also highlight the fact that in practice, there will be gaps between the GPP regulations and implementation. While some places might require a GPP without legal need, others will not implement it despite a legal obligation. The GPP regulations should have standardised epidemiological criteria, be implemented gradually, remain flexible, and change according to the epidemiological risks.

Vaccine distribution in the Global South has created opportunities for vaccine-developing countries to improve their international reputations. Leveraging a panel survey conducted in early 2021, we evaluate whether “vaccine diplomacy” affects trust in foreign governments in six Latin American countries. Among vaccinated respondents, we find that trust in the government of the country that they believed developed their vaccine increased relative to trust in the governments of other foreign powers. Furthermore, providing information about the aggregate distribution of vaccines within a respondent’s country increased vaccine-eligible respondents’ trust in the governments of countries from which more vaccines were delivered. In each case, greater trust principally reflects updated perceptions of a common good motivation. Our empirical findings suggest that vaccine distribution—especially for China, but for other vaccine-developing countries as well—can cultivate favorable international public opinion. This may in turn facilitate great powers’ economic, political, or military foreign policy goals. --- This directory replicates the analysis in "Vaccine Diplomacy: How COVID-19 Vaccine Distribution in Latin America Increases Trust in Foreign Governments," by Barham, Daly, Gerez, Marshall, and Pocasangre. Be sure to read the readme.txt file before running the code.

Current WHO/UNICEF estimates of routine childhood immunization coverage reveal the largest sustained decline in uptake in three decades with pronounced setbacks across Africa. Although the COVID-19 pandemic has induced significant supply and delivery disruptions, the impact of the pandemic on vaccine confidence is less understood. We here examine trends in vaccine confidence across eight sub-Saharan countries between 2020 and 2022 via a total of 17,187 individual interviews, conducted via a multi-stage probability sampling approach and cross-sectional design and evaluated using Bayesian methods. Multilevel regression combined with poststratification weighting using local demographic information yields national and sub-national estimates of vaccine confidence in 2020 and 2022 as well as its socio-demographic associations. We identify declines in perceptions toward the importance of vaccines for children across all eight countries, with mixed trends in perceptions toward vaccine safety and effectiveness. We find that COVID-19 vaccines are perceived to be less important and safe in 2022 than in 2020 in six of the eight countries, with the only increases in COVID-19 vaccine confidence detected in Ivory Coast. There are substantial declines in vaccine confidence in the Democratic Republic of Congo and South Africa, notably in Eastern Cape, KwaZulu-Natal, Limpopo, and Northern Cape (South Africa) and Bandundu, Maniema, Kasaï-Oriental, Kongo-Central, and Sud-Kivu (DRC). While over 60-year-olds in 2022 have higher vaccine confidence in vaccines generally than younger age groups, we do not detect other individual-level socio-demographic associations with vaccine confidence at the sample sizes studied, including sex, age, education, employment status, and religious affiliation. Understanding the role of the COVID-19 pandemic and associated policies on wider vaccine confidence can inform post-COVID vaccination strategies and help rebuild immunization system resilience.

About this Dataset

The data contains the following information:

Country- this is the country for which the vaccination information is provided; Country ISO Code - ISO code for the country; Date - date for the data entry; for some of the dates we have only the daily vaccinations, for others, only the (cumulative) total; Total number of vaccinations - this is the absolute number of total immunizations in the country; Total number of people vaccinated - a person, depending on the immunization scheme, will receive one or more (typically 2) vaccines; at a certain moment, the number of vaccination might be larger than the number of people; Total number of people fully vaccinated - this is the number of people that received the entire set of immunization according to the immunization scheme (typically 2); at a certain moment in time, there might be a certain number of people that received one vaccine and another number (smaller) of people that received all vaccines in the scheme; Daily vaccinations (raw) - for a certain data entry, the number of vaccination for that date/country; Daily vaccinations - for a certain data entry, the number of vaccination for that date/country; Total vaccinations per hundred - ratio (in percent) between vaccination number and total population up to the date in the country; Total number of people vaccinated per hundred - ratio (in percent) between population immunized and total population up to the date in the country; Total number of people fully vaccinated per hundred - ratio (in percent) between population fully immunized and total population up to the date in the country; Number of vaccinations per day - number of daily vaccination for that day and country; Daily vaccinations per million - ratio (in ppm) between vaccination number and total population for the current date in the country; Vaccines used in the country - total number of vaccines used in the country (up to date); Source name - source of the information (national authority, international organization, local organization etc.); Source website - website of the source of information;

Tasks: Track the progress of COVID-19 vaccination What vaccines are used and in which countries? What country is vaccinated more people? What country is vaccinated a larger percent from its population?

This data is valuble in relation to the health, financial, and engineering sectors.

Category

Health & Medicine

Keywords

Health,Medicine,covid-19,dataset,progress

Row Count

5824

Price

$120.00

COVID-19 Vaccines-Production Capacity & Development Timeline Market Outlook

According to our latest research, the global COVID-19 vaccines market size reached USD 40.2 billion in 2024, reflecting a significant contraction from the pandemic’s peak but remaining a critical segment of the global biopharmaceutical industry. The market is projected to grow at a CAGR of 3.7% from 2025 to 2033, reaching a forecasted value of USD 56.7 billion by 2033. This growth is primarily driven by the ongoing need for booster vaccinations, the emergence of new viral variants, and sustained investments in vaccine research and production capabilities worldwide. The market’s resilience is further supported by government procurement programs and the expansion of vaccine access in emerging economies.

The evolution of the COVID-19 vaccines market is shaped by several growth factors, notably the persistent circulation of SARS-CoV-2 and the continuous emergence of new variants that challenge existing immunity levels. Governments and health organizations worldwide remain vigilant, prioritizing the development and distribution of updated vaccines to counter variant-driven outbreaks. The introduction of bivalent and multivalent vaccines, designed to offer protection against multiple strains, has spurred ongoing demand. Furthermore, the increasing reliance on annual or biannual booster doses for vulnerable populations, such as the elderly and immunocompromised individuals, ensures a steady baseline for vaccine consumption. The integration of COVID-19 vaccination into routine immunization schedules is also anticipated to contribute to market stability over the forecast period.

Another key driver is the remarkable progress in vaccine technology, particularly the rapid advancement and deployment of mRNA vaccine platforms. The success of mRNA vaccines has not only revolutionized the response to COVID-19 but has also accelerated research and development for other infectious diseases. This technological leap has encouraged investments in flexible manufacturing infrastructure, enabling faster adaptation to emerging threats and enhancing global production capacity. Additionally, partnerships between pharmaceutical companies, governments, and contract manufacturing organizations (CMOs) have optimized supply chains, improved scalability, and facilitated technology transfer to developing regions. These collaborative efforts are essential for maintaining readiness against future pandemics and for addressing ongoing global health challenges.

Market growth is further bolstered by proactive government policies and international collaborations aimed at ensuring equitable vaccine distribution. Initiatives such as COVAX and bilateral agreements have played a crucial role in expanding vaccine access to low- and middle-income countries, thereby stimulating demand and supporting market expansion. The increasing participation of private procurement channels, including hospitals, clinics, and pharmacies, has diversified distribution networks and improved accessibility for broader populations. Moreover, the push for localized manufacturing and regulatory harmonization is streamlining vaccine approval processes and reducing dependency on a limited number of global suppliers. These trends collectively underpin the sustained growth trajectory of the COVID-19 vaccines market.

Regionally, North America and Europe continue to dominate the COVID-19 vaccines market, accounting for the largest shares due to robust healthcare infrastructure, high vaccination rates, and substantial government funding. However, the Asia Pacific region is exhibiting the fastest growth, driven by large-scale immunization campaigns, expanding manufacturing capabilities, and rising awareness about the importance of vaccination. Countries such as China and India are emerging as significant players in both vaccine production and consumption, supported by favorable policy frameworks and increasing investments in biotechnology. Latin America and the Middle East & Africa are also witnessing gradual improvements in vaccine coverage, although challenges related to infrastructure and affordability persist. Overall, the regional dynamics are expected to evolve as global efforts intensify to achieve comprehensive vaccine coverage and pandemic preparedness.

As of December 23, 2022, around 80 percent of the population of the United States had been given at least one dose of a COVID-19 vaccination. This statistic shows the percentage of population in select countries and territories worldwide that had received a COVID-19 vaccination as of December 23, 2022.

###

The data regarding the progress of covid 19 vaccination all across the data

Content

The data was taken from the Newyork Times covid vaccination tracker You can see the data from the website:https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html I have personally extracted the data and cleaned it so that you guys can use it better

Acknowledgements

My friend https://www.kaggle.com/anandhuh inspired me to create this dataset

Inspiration

With the data we can see the vaccination statistics among all countries in the world and understand the state that the whole world is now standing in case of covid-19 vaccinations, which may help in further actions regarding this matter1.

COVID-19 vaccination rates slowed in many countries during the second half of 2021, along with the emergence of vocal opposition, particularly to mandated vaccinations. Who are those resisting vaccination? Under what conditions do they change their minds? Our 3-wave representative panel survey from Germany allows us to estimate the dynamics of vaccine opposition, providing the following answers. Without mandates it may be difficult to reach and to sustain the near universal level of repeated vaccinations apparently required to contain the Delta, Omicron and likely subsequent variants. But mandates substantially increase opposition to vaccination. We find that few were opposed to voluntary vaccination in all three waves of the survey. They are just 3.3 percent of our panel, a number that we demonstrate is unlikely to be the result of response error. In contrast, the fraction consistently opposed to enforced vaccinations is 16.5 percent. Under both policies, those consistently opposed and those switching from opposition to supporting vaccination are socio-demographically virtually indistinguishable from other Germans. Thus, the mechanisms accounting for the dynamics of vaccine attitudes may apply generally across societal groups. What differentiates them from others are their beliefs about vaccination effectiveness, trust in public institutions, and whether they perceive enforced vaccination as a restriction on their freedom. We find that changing these beliefs is both possible and necessary to increase vaccine willingness, even in the case of mandates. An inference is that well-designed policies of persuasion and enforcement will be complementary, not alternatives.

This data set provides the data and Stata code used for the article. A detailed description of the variables is available from the corresponding publication. Please cite our paper if you use the data.

Approved COVID-19 Vaccines Market Outlook

The global market size for approved COVID-19 vaccines stood at approximately USD 45 billion in 2023 and is projected to reach around USD 78 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This substantial growth is primarily driven by continuous advancements in vaccine technology, increasing global vaccination drives, and the emergence of new variants necessitating booster doses.

One of the primary growth factors for the approved COVID-19 vaccines market is the ongoing need for booster vaccinations. As new variants of the virus emerge, vaccine manufacturers are continuously enhancing existing vaccines to tackle these variants effectively. This continuous innovation ensures sustained demand for updated vaccines, thereby propelling market growth. Additionally, governments worldwide are investing heavily in vaccination programs to achieve herd immunity, further boosting market size. Initiatives like COVAX, which aim to provide equitable vaccine access, are also significant contributors to market expansion.

Another crucial factor driving market growth is the increased awareness and acceptance of vaccines among the global population. Intensive public health campaigns and educational movements have led to a higher acceptance rate of vaccines, reducing vaccine hesitancy. This trend is particularly significant in emerging economies where initial vaccine skepticism was high. The successful roll-out of initial vaccine doses has built public confidence, thereby increasing the uptake of booster doses and new vaccine variants.

The collaboration between pharmaceutical companies and governments has also played a pivotal role in the growth of the COVID-19 vaccines market. Strategic partnerships for vaccine production, distribution, and administration have streamlined the supply chain, making vaccines more accessible to the public. These collaborations have also facilitated bulk purchasing agreements, which have provided cost advantages and enhanced market penetration across various regions. Moreover, the establishment of new manufacturing facilities and the expansion of existing ones have significantly accelerated vaccine production capabilities.

The development of the COVID-19 RNA Vaccine has been a groundbreaking advancement in the fight against the pandemic. Unlike traditional vaccines, RNA vaccines work by introducing a small piece of genetic material from the virus into the body, prompting an immune response without using a live virus. This innovative approach has allowed for rapid development and deployment, significantly contributing to the global vaccination efforts. The flexibility of RNA technology also enables quick updates to the vaccine to address new variants, ensuring continued protection as the virus evolves. This adaptability has made RNA vaccines a crucial tool in achieving widespread immunity and controlling the spread of COVID-19.

Regionally, North America leads the market due to its advanced healthcare infrastructure and early adoption of vaccination programs. Europe follows closely, with significant contributions from countries like Germany, France, and the UK. The Asia Pacific region is witnessing rapid growth, driven by substantial investments in healthcare infrastructure and large-scale vaccination drives in countries like India and China. Meanwhile, Latin America and the Middle East & Africa are gradually catching up, supported by international aid and improving healthcare systems. The regional diversity ensures a balanced growth outlook for the global market.

Vaccine Type Analysis

The market for approved COVID-19 vaccines is segmented into various types, including mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, have gained significant traction due to their high efficacy rates and the rapid speed of development. The flexibility of mRNA technology to adapt swiftly to new variants has positioned them as a frontrunner in the market. This segment is expected to continue its dominance, supported by ongoing research and development activities aimed at enhancing vaccine formulations and delivery mechanisms.

Vector vaccines, which use a modified virus to deliver genetic material into cells, represent another significant segment. AstraZeneca and Johnson & Johnson are key players in t

COVID-19 Vaccines Market Outlook

According to our latest research, the global COVID-19 vaccines market size stood at USD 34.2 billion in 2024, reflecting a significant contraction from the pandemic’s peak but still underscoring the ongoing demand for booster shots, variant-specific formulations, and immunization programs. The market is expected to reach USD 14.7 billion by 2033, registering a compound annual growth rate (CAGR) of 9.8% over the forecast period. This trajectory is driven by persistent global immunization efforts, the emergence of new SARS-CoV-2 variants, and the integration of COVID-19 vaccines into routine vaccination schedules.

The primary growth factor for the COVID-19 vaccines market is the continued evolution of the SARS-CoV-2 virus, leading to the emergence of new variants. These variants often exhibit mutations that may partially evade immunity conferred by previous infection or vaccination, necessitating the development and deployment of updated vaccine formulations. Pharmaceutical companies are investing in next-generation vaccines, including multivalent and pan-coronavirus candidates, to address these challenges. Governments and health organizations remain vigilant, maintaining stockpiles and rolling out booster campaigns, especially for high-risk populations such as the elderly and immunocompromised. The integration of COVID-19 vaccines with seasonal influenza programs is also being explored, potentially driving market growth through combined immunization initiatives.

Another crucial driver is the growing emphasis on equitable vaccine access, particularly in low- and middle-income countries. International collaborations, such as COVAX and bilateral donation agreements, have played a vital role in expanding vaccine reach beyond high-income nations. As the acute phase of the pandemic subsides, there is a strategic shift towards sustained immunization efforts, with many countries incorporating COVID-19 vaccines into their national immunization schedules. This long-term approach is expected to stabilize demand and support market growth, albeit at a lower volume compared to the pandemic’s initial years. Additionally, the development of pediatric and variant-adapted vaccines is broadening the addressable market, ensuring ongoing relevance for manufacturers.

Technological advancements in vaccine platforms, particularly mRNA and protein subunit technologies, are reshaping the market landscape. The success of mRNA vaccines has spurred further research into their application for other infectious diseases, creating a pipeline of innovative products. These platforms offer advantages such as rapid adaptability to emerging variants and scalable manufacturing, making them attractive for both public health authorities and commercial stakeholders. The competitive environment is also fostering partnerships between pharmaceutical companies, biotechnology firms, and academic institutions to accelerate research and development. Such collaborations are expected to yield more effective and durable vaccines, further propelling the market’s evolution.

From a regional perspective, North America and Europe continue to lead the market in terms of revenue, owing to robust healthcare infrastructure, high vaccination coverage, and proactive government policies. The Asia Pacific region is witnessing the fastest growth, driven by large population bases, increasing healthcare investments, and expanding immunization programs. Latin America and the Middle East & Africa are gradually improving their vaccination rates, supported by international aid and local manufacturing initiatives. The regional dynamics are influenced by factors such as regulatory approvals, supply chain logistics, and public acceptance of vaccines, which collectively shape the market’s trajectory across different geographies.

Vaccine Type Analysis

The COVID-19 vaccines market is segmented by vaccine type into mRNA vaccines, viral vector vaccines, protein subunit vaccines, inacti

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

AimsOver the past 2 years, the vaccine conspiracy beliefs construct has been used in a number of different studies. These publications have assessed the determinants and outcomes of vaccine conspiracy beliefs using, in some cases, pooled data from different countries, and compared the results across these contexts. However, studies often do not consider measurement invariance as a necessary requirement for comparative analyses. Therefore, the aim of this study was to develop and evaluate the cross-cultural MI of the COVID-19 Vaccine Conspiracy Beliefs Scale (COVID-VCBS) in 12 Latin American countries.MethodsConfirmatory factor analysis, item response theory analysis and alignment method were applied to test measurement invariance in a large number of groups.ResultsThe COVID-VCBS showed robust psychometric properties and measurement invariance for both factor loadings and crosstabs. Also, a higher level of acceptance of conspiracy beliefs about vaccines is necessary to respond to higher response categories. Similarly, greater acceptance of conspiracy beliefs about COVID-19 vaccines was related to a lower intention to be vaccinated.ConclusionThe results allow for improved understanding of conspiracy beliefs about COVID-19 vaccines in the countries assessed; furthermore, they provide researchers and practitioners with an invariant measure that they can use in cross-cultural studies in Latin America. However, further studies are needed to test invariance in other countries, with the goal of developing a truly international measure of conspiracy beliefs about COVID-19 vaccines.

BackgroundThe COVID-19 pandemic has disrupted routine childhood vaccinations worldwide with low- and middle-income countries (LMICs) most affected. This study aims to quantify levels of disruption to routine vaccinations in LMICs.MethodsA systematic review (PROSPERO CRD42021286386) was conducted of MEDLINE, Embase, Global Health, CINAHL, Scopus and MedRxiv, on the 11th of February 2022. Primary research studies published from January 2020 onwards were included if they reported levels of routine pediatrics vaccinations before and after March 2020. Study appraisal was performed using NHLBI tool for cross-sectional studies. Levels of disruption were summarized using medians and interquartile ranges.ResultsA total of 39 cross-sectional studies were identified. These showed an overall relative median decline of −10.8% [interquartile range (IQR) −27.6%, −1.4%] across all vaccines. Upper-middle-income countries (upper-MICs) (−14.3%; IQR −24.3%, −2.4%) and lower-MICs (−18.0%; IQR −48.6%, −4.1%) showed greater declines than low-income countries (−3.1%; IQR −12.8%, 2.9%), as did vaccines administered at birth (−11.8%; IQR −27.7%, −3.5%) compared to those given after birth (−8.0%; IQR −28.6%, −0.4%). Declines during the first 3 months of the pandemic (−8.1%; IQR −35.1%, −1.4%) were greater than during the remainder of 2020 (−3.9%; IQR −13.0%, 11.4%) compared to baseline.ConclusionThere has been a decline in routine pediatric vaccination, greatest in MICs and for vaccines administered at birth. Nations must prioritize catch-up programs alongside public health messaging to encourage vaccine uptake.Systematic review registrationIdentifier: CRD42021286386.